Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $331,686.09 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 8,667 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $38.27, for a total transaction of $331,686.09. Following the transaction, the director owned 10,500 shares in the company, valued at approximately $401,835. The trade was a 45.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Robert Glassman also recently made the following trade(s):

• On Wednesday, September 9th, Robert Glassman sold 8,000 shares of Pharvaris stock. The shares were sold at an average price of $37.55, for a total transaction of $300,400.00.

Pharvaris Trading Up 2.5%

Shares of PHVS traded up $0.95 during midday trading on Thursday, reaching $38.50. The stock had a trading volume of 236,024 shares, compared to its average volume of 404,961. The firm has a market cap of $2.52 billion, a PE ratio of -12.62 and a beta of -2.33. The firm has a 50 day simple moving average of $35.31 and a 200-day simple moving average of $31.63. Pharvaris N.V. has a one year low of $20.65 and a one year high of $43.25.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, research analysts forecast that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Institutional Trading of Pharvaris

Institutional investors have recently added to or reduced their stakes in the company. venBio Partners LLC acquired a new position in shares of Pharvaris during the 2nd quarter worth approximately $160,569,809. 5AM Venture Management LLC acquired a new stake in shares of Pharvaris in the second quarter valued at approximately $27,581,008. BlackRock Inc. bought a new stake in shares of Pharvaris in the second quarter valued at approximately $26,677,000. Elmind Capital LP bought a new stake in shares of Pharvaris in the second quarter valued at approximately $18,180,435. Finally, Seven Fleet Capital Management LP grew its position in Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after buying an additional 457,804 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have recently commented on PHVS shares. UBS Group set a $79.00 target price on Pharvaris in a research note on Wednesday, September 9th. Guggenheim lifted their price objective on shares of Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Wells Fargo & Company upped their price objective on shares of Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Oppenheimer reissued an “outperform” rating and issued a $75.00 price objective on shares of Pharvaris in a research report on Tuesday, September 8th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research note on Tuesday, September 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and an average price target of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.